Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.49 |
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.49 |
| ▸ | SCD | O00767 | 4/20 | 0.46 |
| ▸ | SCD5 | Q86SK9 | 4/20 | 0.46 |
| ▸ | CCNC | P24863 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.40 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.40 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22729509 | 0.97 | HSP90AA1 (0.46) | HSP90AA1HSP90AB1RIPK1SCDSCD5 | |
| SCHEMBL22729502 | 0.94 | RIPK1 (0.47) | HSP90AA1HSP90AB1RIPK1SCDSCD5 | |
| SCHEMBL22754965 | 0.88 | HSD17B10 (0.51) | SCDSCD5 | |
| SCHEMBL22729779 | 0.87 | ROCK2 (0.43) | HSP90AA1HSP90AB1RIPK1SCDSCD5 | |
| SCHEMBL23116411 | 0.86 | ROCK2 (0.48) | SCD5 | |
| SCHEMBL29839310 | 0.86 | RIPK1 (0.42) | HSP90AA1HSP90AB1RIPK1SCDSCD5 | |
| SCHEMBL22729681 | 0.86 | RIPK1 (0.42) | HSP90AA1HSP90AB1RIPK1SCDSCD5 | |
| SCHEMBL23116377 | 0.85 | HSD17B10 (0.48) | SCDSCD5 | |
| SCHEMBL23116387 | 0.84 | HSP90AA1 (0.56) | HSP90AA1HSP90AB1SCD5 | |
| SCHEMBL29839290 | 0.84 | HSP90AA1 (0.56) | HSP90AA1HSP90AB1SCD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459325-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-04 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3747885-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | HSP90AA1 3000/4885HSP90AB1 2618/4885RIPK1 3562/4885 |
| US-11459325-B2 | Heterocyclic compound | GBA1, GBA2, GALC | HSP90AA1 3030/4885HSP90AB1 2624/4885RIPK1 3482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.